Gholam-Mostafaei Fahimeh Sadat, Azimirad Masoumeh, Naseri Kaveh, Nabavi-Rad Ali, Asadzadeh Aghdaei Hamid, Shahrokh Shabnam, Ebrahimi Daryani Nasser, Yadegar Abbas, Zali Mohammad Reza
Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Foodborne and Waterborne Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Front Microbiol. 2023 Feb 24;14:1147945. doi: 10.3389/fmicb.2023.1147945. eCollection 2023.
Patients with inflammatory bowel disease (IBD) are at a greater risk for the recurrence of infection (rCDI) that is triggered by intestinal microbiota dysbiosis. Fecal microbiota transplantation (FMT) has emerged as a highly effective therapeutic option for this complication. However, little is known about the impact of FMT on intestinal microbiota alterations in rCDI patients suffering from IBD. In this study, we aimed to investigate post-FMT intestinal microbiota alterations in Iranian rCDI patients with underlying IBD.
A total of 21 fecal samples were collected including 14 samples pre- and post-FMT and 7 samples from healthy donors. Microbial analysis was performed by quantitative real-time PCR (RT-qPCR) assay targeting the 16S rRNA gene. The pre-FMT profile and composition of the fecal microbiota were compared to the microbial changes of samples collected 28 days after FMT.
Overall, the fecal microbiota profile of recipients was more similar to donor samples after the transplantation. We observed a significant increase in the relative abundance of Bacteroidetes post-FMT, compared to the pre-FMT microbial profile. Furthermore, there were remarkable differences between the microbial profile of pre-FMT, post-FMT, and healthy donor samples by PCoA analysis based on the ordination distance. This study demonstrates FMT as a safe and effective approach to restore the indigenous composition of the intestinal microbiota in rCDI patients and ultimately results in the treatment of concurrent IBD.
炎症性肠病（IBD）患者因肠道微生物群失调引发感染复发（rCDI）的风险更高。粪便微生物群移植（FMT）已成为治疗这一并发症的高效疗法。然而，对于FMT对患有IBD的rCDI患者肠道微生物群改变的影响知之甚少。在本研究中，我们旨在调查患有潜在IBD的伊朗rCDI患者FMT后的肠道微生物群改变。
共收集21份粪便样本，包括14份FMT前后的样本以及7份来自健康供体的样本。通过针对16S rRNA基因的定量实时PCR（RT-qPCR）分析进行微生物分析。将FMT前粪便微生物群的特征和组成与FMT后28天采集样本的微生物变化进行比较。
总体而言，移植后受体的粪便微生物群特征与供体样本更为相似。与FMT前的微生物特征相比，我们观察到FMT后拟杆菌门的相对丰度显著增加。此外，基于排序距离的主坐标分析（PCoA）显示，FMT前、FMT后和健康供体样本的微生物特征存在显著差异。本研究表明，FMT是恢复rCDI患者肠道微生物群固有组成的安全有效方法，并最终可治疗并发的IBD。
